Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA40114. December 2021|In Portfolio News|By eazee-designstudioIImmatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb, today announced that they have entered into a license, development and commercialization agreement for Immatics’ TCR Bispecific candidate, IMA401. PrevNext
